Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia
PLHIV receiving a tenofovir, lamivudine, and dolutegravir based regimen particularly females, aged 38-54 years, those with limited physical activity, follow-up durations of 6-24 months, advanced disease stages, and a detectable viral load at therapy initiation should be closely monitored for weight gain. Proactive surveillance in these patient groups is crucial to optimize therapeutic outcomes and address potential health concerns associated with weight changes.
Authors
- Gashaw Sisay Chanie (ORCID: https://orcid.org/0000-0001-9585-4196)
- Mihret Melese (ORCID: https://orcid.org/0000-0002-5685-3585)
- Wagaye Atalay
- Yonas Sisay Aragie (ORCID: https://orcid.org/0000-0002-7053-5700)
- Rahel Belete Abebe (ORCID: https://orcid.org/0000-0002-2560-2951)
- Gizachew Kassahun Bizuneh (ORCID: https://orcid.org/0000-0002-1096-4773)
- Tirsit Ketsela Zeleke (ORCID: https://orcid.org/0000-0003-3528-0703)
- Zemenu Wube Bayleyegn
Institutions
- University of Gondar (ET)
- Debre Markos University (ET)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fphar.2025.1394458
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00